# EDGAR Filing Document

**Accession Number:** 0001659323
**File Stem:** 0001193125-26-022666
**Filing Date:** 2026-1
**Character Count:** 3787
**Document Hash:** 34faf8784b54e6a8325af678baff4b67
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-022666.hdr.sgml**: 20260126

**ACCESSION NUMBER**: 0001193125-26-022666

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260126

**DATE AS OF CHANGE**: 20260126

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Iterum Therapeutics plc
- **CENTRAL INDEX KEY:** 0001659323
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38503
- **FILM NUMBER:** 26560842

**BUSINESS ADDRESS:**
- **STREET 1:** 3 DUBLIN LANDINGS
- **STREET 2:** NORTH WALL QUAY
- **CITY:** DUBLIN 1
- **STATE:** L2
- **ZIP:** D01 H104
- **BUSINESS PHONE:** (872) 225-6077

**MAIL ADDRESS:**
- **STREET 1:** 3 DUBLIN LANDINGS
- **STREET 2:** NORTH WALL QUAY
- **CITY:** DUBLIN 1
- **STATE:** L2
- **ZIP:** D01 H104

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Iterum Therapeutics Ltd
- **DATE OF NAME CHANGE:** 20151124

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the**

**Securities Exchange Act of 1934**

**(Amendment No.)**

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:

**☐** Preliminary Proxy Statement

**☐** **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

**☐** Definitive Proxy Statement

**☒** Definitive Additional Materials

**☐** Soliciting Material under §240.14a-12

**Iterum Therapeutics plc**

**(Name of Registrant as Specified In Its Charter)**

------

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**

Payment of Filing Fee (Check all boxes that apply):

**☒** No fee required.

------

**☐** Fee paid previously with preliminary materials.

**☐** Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

------

*[The following communication was sent or made available commencing on January 26, 2026*

*to certain shareholders of Iterum Therapeutics plc]*

January 26, 2026

Dear Shareholders:

We are reaching out as a reminder to **<u>please VOTE YOUR SHARES</u>** in advance of our extraordinary general meeting of shareholders scheduled on February 18, 2026 (the "EGM"). The four proposals being voted on at the EGM are described in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on January 2, 2026 (the "Proxy Statement").

Our board of directors has unanimously recommended that shareholders vote **FOR** each of the proposals, as does leading proxy advisory firm, Institutional Shareholder Services. Please vote in favor of each proposal today to support Iterum Therapeutics plc.

**YOUR VOTE IS IMPORTANT – REGARDLESS OF HOW MANY SHARES YOU OWN**

**<u>If you have not voted yet, please do so today</u>**. Your vote must be cast no later than February 17, 2026, at 11:59 PM ET to be counted, if you do not plan to attend the meeting in person. Every vote counts.

***VOTING CAN BE DONE QUICKLY AND EASILY***

Since the meeting is fast approaching, we encourage you to please vote either online or by phone by following the instructions provided in the Proxy Statement.

If you have any questions or need assistance with voting, please contact our proxy solicitor Campaign Management by phone toll free at 1-888-725-4553 or via email at info@campaign-mgmt.com

Thank you for your support.

![img49790017_0.jpg](img49790017_0.jpg)

________________________

Corey N. Fishman

President and Chief Executive Officer

------